Pharmaceuticals News and Research

RSS

Enrollment complete in Alnylam's ALN-RSV01 Phase IIb study for RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has completed patient enrollment in its Phase IIb study with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection.

29 Nov 2011

FDA approves Watson's ANDA for generic Yaz oral contraceptive

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Vestura (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer's Yaz oral contraceptive product.

29 Nov 2011

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the European Commission (EC) has extended the therapeutic indication for Soliris® (eculizumab) to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS).

29 Nov 2011

BioLineRx reports third quarter net loss of NIS 7.9 million

BioLineRx Ltd., a biopharmaceutical development company, today reported its results for the third quarter ending September 30, 2011.

29 Nov 2011

New technique to accomplish 'accelerated serendipity' using robotics

Scientists can now take that "a-ha" moment to go with a method Princeton University researchers developed - and successfully tested - to speed up the chances of an unexpected yet groundbreaking chemical discovery.

29 Nov 2011

New research institute at The University of Texas MD Anderson Cancer Center

Academic and government leaders announced today the establishment of a major new research institute at The University of Texas MD Anderson Cancer Center that will blend the best attributes of academic and industrial research to identify and validate new cancer targets, convert such scientific knowledge into new cancer drugs, and advance these novel agents into innovative clinical trials.

29 Nov 2011

HealthWarehouse.com launches pre-order program for generic Lipitor

HealthWarehouse.com, Inc., a leading VIPPS-accredited, retail mail-order pharmacy, announced today the launch of its pre-order program to enable consumers immediate access to Atorvastatin (Generic Lipitor®) on Dec. 5. HealthWarehouse will offer the medication at up to 50 percent less than the branded versions from retail pharmacies.

29 Nov 2011

Ferrer introduces citicoline oral solution medical food

Ferrer Therapeutics, the U.S. subsidiary of the international pharmaceutical group, Ferrer Grupo, is introducing CerAxon- Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline, a nutrient naturally produced by the body and found in the brain.

29 Nov 2011

Improving patient adherence to medications for chronic diseases can reduce overall treatment costs

Avi Dor, Ph.D., professor in the Department of Health Policy, GW School of Public Health and Health Services, was a co-author of a study, in collaboration with Teva Pharmaceuticals, that found that higher patient adherence to disease modifying therapies, like glatiramer acetate (GA), an immunomodulator drug currently used to treat multiple sclerosis, reduced inpatient costs, outpatient costs, and other medical expenses in a national sample of multiple sclerosis patients.

29 Nov 2011

New compound circumvents drug-efflux pumps associated with Gram-positive bacteria

It's no wonder that medicine's effort to combat bacterial infections is often described as an arms race. When new drugs are developed to combat infections, the bacterial target invariably comes up with a deterrent.

29 Nov 2011

State roundup: Calif. hospital allegedly overbilling Medicare; Wash. hospitals ER 'boom'; Rehab scams in Florida?

Health policy news from California, Florida, Washington state, Oregon, Vermont and Texas.

28 Nov 2011

GVK Biosciences and Moulder Center at Temple University enter drug discovery alliance

GVK Biosciences, Asia's leading drug discovery research & development organization, announced today that it has entered into a drug discovery alliance with the Moulder Center for Drug Discovery Research at Temple University.

28 Nov 2011

Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that they have initiated a Phase 3 clinical trial evaluating the efficacy and safety of EYLEA (aflibercept) Injection in the neovascular form of age-related macular degeneration (wet AMD) in China.

28 Nov 2011

China Nepstar Chain Drugstore third quarter revenue increases 1.9% to RMB608.6 million

China Nepstar Chain Drugstore Ltd., the largest retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the third quarter ended September 30, 2011.

28 Nov 2011

Drug for midnight waking gets FDA approval

Transcept Pharmaceuticals Inc. has received the Food and Drug Administration (FDA) approval for its drug Intermezzo - a drug that can help people get back to sleep after waking in the middle of the night. The treatment contains a low-dose of zolpidem tartrate, the active ingredient in Paris-based Sanofi’s sleeping pill Ambien.

27 Nov 2011

Moleac launches NurAiD II in France and Belgium

Biopharmaceutical Company Moleac has announced the launch in France and Belgium of NurAiD II. NurAiD II is a natural health supplement engineered to stimulate neuroplasticity and recovery.

25 Nov 2011

Merck agrees to pay $950 million in Vioxx settlement

The pharmaceutical giant will pay a $321 million criminal fine and a $628 million civil settlement.

24 Nov 2011

Five ways pharmaceutical companies can address NTDs

In this Forbes opinion piece, journalist Sarika Bansal examines five ways in which pharmaceutical companies can address neglected tropical diseases (NTDs), including creating cross-sectorial research partnerships for neglected diseases; joining patent pools for neglected diseases; donating drugs for neglected diseases; creating facilities dedicated to neglected disease research; and allowing scientists to work on neglected disease, both formally and informally.

24 Nov 2011

Takeda submits alogliptin plus metformin NDA to FDA for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited (Takeda) announced today that its wholly-owned subsidiary Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for the fixed-dose combination therapy alogliptin/metformin, which combines alogliptin with metformin in a single tablet.

24 Nov 2011

Transcept receives FDA approval for Intermezzo to treat insomnia

The U.S. Food and Drug Administration today approved Intermezzo (zolpidem tartrate sublingual tablets) for use as needed to treat insomnia characterized by middle-of-the-night waking followed by difficulty returning to sleep.

23 Nov 2011